EpiVax Receives NIH Grant for $390,000 to Optimize HIV Vaccine Delivery
"The recent failure of the investigational HIV vaccine tested in the Phase
II clinical trial known as STEP is a strong indicator that more traditional
approaches to vaccine design and delivery are simply not going to work for
HIV. That's why the EpiVax brand of "outside the box" thinking was funded; the
world is looking for safer, more effective ways to prevent AIDS," said Dr.
Using the grant funding from the NIH, EpiVax will develop a pro-inflammatory and non-tolerogenic HIV vaccine delivery system based on the dendritic cell targeting anti-DEC-205 antibody. The success of anti-DEC-205 as a vaccine carrier is dependent on co-administration of non-specific dendritic cell maturation factors such as CD40-ligand. In their absence, anti-DEC-205 induces antigen-specific tolerance rather than immunity. EpiVax reasons that regulatory T-cell epitopes contained in anti-DEC-205 promote a tolerogenic reaction that is only overcome through the coadministration of clinically dangerous or untested non-specific immuno-stimulators. This idea is based on EpiVax' discovery of a set of natural regulatory T-cell epitopes derived from human immunoglobulins that induce tolerance by stimulating regulatory T cells. EpiVax has already verified experimentally that these epitopes cause antigen-specific expansion of regulatory T cells and suppress inflammatory immune responses.
The NIH award will enable EpiVax to develop a modified pro-inflammatory and non-tolerogenic anti-DEC-205 antibody. Modification of regulatory T-cell epitopes is expected to significantly diminish tolerogenicity, enabling use of anti-DEC-205 as a stand-alone HIV antigen delivery system that obviates the dangers associated with non-specific activation of the immune system.
Epitope modification is an immunomodulatory approach EpiVax previously developed to reduce immunogenicity of protein therapeutics. Here, EpiVax will substitute key amino acids in the regulatory T-cell epitopes with those that are experimentally shown to interfere with MHC binding to reduce tolerogenicity.
Vaccines According to the World Health Organization, "The development of a safe and effective vaccine is hampered by the high genetic variability of HIV, the lack of knowledge of immune correlates of protection, the absence of relevant and predictive animal models, and the complexity of the implementation of efficacy trials, especially in developing countries."
This grant award is the 5th consecutive NIH or foundation award granted to
EpiVax in the last year, for a total of more than
Tregitope is a set of peptides that induce the body's own natural regulatory T cells. When administered in conjunction with other antigens or protein immunogens, the response to these immunogens is diminished and altered if the antigen/immunogens are co-administered with Epi- 13. Preliminary in vitro and in vivo studies indicate that the modification of the immune response is due to the induction of natural T reg cells. Read the original article online at http://www.pubmedcentral.nih.gov/.
About National Institute of Allergy and Infectious Diseases (NIAID)
The National Institute of Allergy and Infectious Diseases (NIAID) conducts
and supports basic and applied research to better understand, treat, and
ultimately prevent infectious, immunologic, and allergic diseases. For more
than 50 years, NIAID research has led to new therapies, vaccines, diagnostic
tests, and other technologies that have improved the health of millions of
SOURCE EpiVax, Inc.
More by this Source
BioAtla Combines EpiVax's Immunogenicity Screening Into Their Express Humanization™ Platform
Apr 24, 2013, 09:00 ET
Why H7N9 (Shanghai 2013) is the new stealth virus and what we can do about it.
Apr 13, 2013, 09:00 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.